Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11517912 | 0.98 | CA12 (0.53) | CA12CA2CA9MEN1KMT2A | |
| SCHEMBL11521671 | 0.98 | CA12 (0.53) | CA12CA2CA9MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL11521152 | 0.98 | CA12 (0.53) | CA12CA2CA9MEN1KMT2A | |
| SCHEMBL1509976 | 0.87 | MEN1 (0.64) | CA2CA9MEN1KMT2APOLB | |
| SCHEMBL11520695 | 0.85 | CA2 (0.58) | CA12CA2CA9POLBCYP1A2 | |
| SCHEMBL7932235 | 0.82 | MAPT (0.62) | MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL2843886 | 0.82 | CA12 (0.56) | CA12CA2CA9MEN1KMT2A | |
| SCHEMBL9912437 | 0.82 | CA12 (0.56) | CA12CA2CA9MEN1KMT2A | |
| SCHEMBL253778 | 0.81 | HDAC1 (0.65) | MEN1KMT2APOLBMAPTL3MBTL1 | |
| SCHEMBL11517909 | 0.81 | MEN1 (0.50) | CA2CA9MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5602277-A | Substituted benzene derivatives useful as neuraminidase inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-02-11 | — | — | US | claimed |
| WO-1996030329-A1 | SUBSTITUTED BENZENE DERIVATIVES USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INCORPORATED (US) | 1996-10-03 | — | — | WO | claimed |
| US-4005222-A | Mucolytic mercaptoacylamidobenzoic and benzenesulfonic acid compounds and process | MEAD JOHNSON & COMPANY (US) | 1977-01-25 | — | — | US | claimed |
| EP-3320921-B1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20180153817-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| EP-3320921-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | Ala Wai Pharma, Inc. (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-2217216-B1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20170157059-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9579383-B2 | Formulations for enhanced bioavailability of orally administered polar agents | ALA WAI PHARMA, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20140072627-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8609139-B2 | Formulations for enhanced bioavailability of orally administered polar agents | ALA WAI PHARMA, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| EP-0524146-A1 | Aminosubstituted Piperazinederivatives | CIBA-GEIGY AG (CH) | 1993-01-20 | — | — | EP | disclosed |
| US-4178301-A | 4-(2-(ACETYLTHIO)ACETAMIDO)BENZOIC ACID AS MUCOLYTIC AGENT | MEAD JOHNSON & COMPANY (US) | 1979-12-11 | — | — | US | disclosed |
| US-4178301-A | 4-(2-(ACETYLTHIO)ACETAMIDO)BENZOIC ACID AS MUCOLYTIC AGENT | MEAD JOHNSON & COMPANY (US) | 1979-12-11 | — | — | US | disclosed |
| US-4132802-A | LIQUEFACTION OF MUCUS | MEAD JOHNSON & COMPANY (US) | 1979-01-02 | — | — | US | disclosed |
| US-4132802-A | LIQUEFACTION OF MUCUS | MEAD JOHNSON & COMPANY (US) | 1979-01-02 | — | — | US | disclosed |
| US-4096277-A | Mucolytic mercaptoacylamidobenzamides and process of using same | MEAD JOHNSON & COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
| US-4096277-A | Mucolytic mercaptoacylamidobenzamides and process of using same | MEAD JOHNSON & COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
| US-4005222-A | Mucolytic mercaptoacylamidobenzoic and benzenesulfonic acid compounds and process | MEAD JOHNSON & COMPANY (US) | 1977-01-25 | — | — | US | disclosed |
| US-4005222-A | Mucolytic mercaptoacylamidobenzoic and benzenesulfonic acid compounds and process | MEAD JOHNSON & COMPANY (US) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157059-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | CA12 484/4885CA2 851/4885CA9 914/4885 |
| US-20180153817-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | CA12 484/4885CA2 851/4885CA9 914/4885 |
| US-20140072627-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | CA12 484/4885CA2 851/4885CA9 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.